SCHEMBL9942884

SCHEMBL9942884

CCOC(=O)c1nc2n(c(=O)c1O)CC1(COS(=O)(=O)c3ccc(C)cc3)CCC2(N(C)C(=O)OCc2ccccc2)CC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.34
POLB P06746 1/20 0.33
ELANE P08246 1/20 0.33
MAPT P10636 2/20 0.33
LMNA P02545 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CYP19A1 P11511 1/20 0.31
CA1 P00915 2/20 0.31
CA2 P00918 2/20 0.31
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
NPY1R P25929 1/20 0.30
MAOB P27338 1/20 0.30
ADORA2A P29274 1/20 0.30
RECQL P46063 1/20 0.30
NPY2R P49146 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9900673 0.85 P2RX7 (0.34) P2RX7POLBELANEMAPTLMNA
SCHEMBL9942931 0.84 KCNH2 (0.34) P2RX7
SCHEMBL9943048 0.80 TP53 (0.35) POLBLMNAKMT2ASMN1; SMN2CA1
SCHEMBL14212557 0.75 P2RX7 (0.35) P2RX7ELANEMAPTLMNASMN1; SMN2
SCHEMBL52427 0.74 ADORA3 (0.36) KDM4EALDH1A1L3MBTL1HPGD
SCHEMBL9942907 0.73 CYP2C9 (0.46) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL9943017 0.73 ELANE (0.33) P2RX7ELANELMNACA1CA2
SCHEMBL9904915 0.71 CYP2C9 (0.38)
SCHEMBL9942882 0.71 RORC (0.32) P2RX7MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL9942949 0.70 CYP2C9 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835411-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-16 US disclosed
US-8835411-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-16 US disclosed
US-20120309698-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2012-12-06 US disclosed
US-20120309698-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2012-12-06 US disclosed
WO-2012078834-A1 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309698-A1 HIV Integrase Inhibitors DNTT, POLB, UNG P2RX7 3911/4885POLB 2/4885ELANE 2590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.